Ligand Pharmaceuticals Analyst Ratings
Ligand Pharmaceuticals Analyst Ratings
| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 08/23/2023 | 40.49% | Benchmark | → $95 | Reiterates | Buy → Buy |
| 08/09/2023 | 112.95% | HC Wainwright & Co. | → $144 | Reiterates | Buy → Buy |
| 07/25/2023 | 62.67% | Barclays | $120 → $110 | Maintains | Overweight |
| 06/02/2023 | 112.95% | HC Wainwright & Co. | $135 → $144 | Reiterates | Buy → Buy |
| 02/21/2023 | 40.49% | Benchmark | → $95 | Reiterates | → Buy |
| 12/23/2022 | 33.1% | Roth Capital | $85 → $90 | Maintains | Buy |
| 11/21/2022 | 77.46% | Barclays | $150 → $120 | Maintains | Overweight |
| 10/25/2022 | 121.83% | Barclays | $157 → $150 | Maintains | Overweight |
| 09/02/2022 | 158.8% | Roth Capital | $185 → $175 | Maintains | Buy |
| 07/05/2022 | 132.18% | Barclays | $165 → $157 | Maintains | Overweight |
| 05/16/2022 | 92.25% | Stephens & Co. | $153 → $130 | Maintains | Overweight |
| 02/22/2022 | 92.25% | Benchmark | $180 → $130 | Maintains | Buy |
| 02/18/2022 | 144.01% | Barclays | $185 → $165 | Maintains | Overweight |
| 09/22/2021 | 166.19% | Barclays | $174 → $180 | Maintains | Overweight |
| 07/30/2021 | 180.98% | Roth Capital | $200 → $190 | Maintains | Buy |
| 05/04/2021 | 180.98% | Barclays | $198 → $190 | Maintains | Overweight |
| 02/04/2021 | 192.81% | Barclays | $145 → $198 | Maintains | Overweight |
| 02/04/2021 | 195.77% | Roth Capital | $195 → $200 | Maintains | Buy |
| 02/04/2021 | 358.44% | HC Wainwright & Co. | $229 → $310 | Maintains | Buy |
| 10/21/2020 | 188.38% | Craig-Hallum | $215 → $195 | Maintains | Buy |
| 09/29/2020 | 188.38% | Roth Capital | $190 → $195 | Reiterates | → Buy |
| 08/04/2020 | 114.43% | Barclays | $134 → $145 | Maintains | Overweight |
| 04/08/2020 | 238.66% | HC Wainwright & Co. | $237 → $229 | Maintains | Buy |
| 03/24/2020 | — | Argus Research | Downgrades | Buy → Hold | |
| 03/10/2020 | — | Guggenheim | Initiates Coverage On | → Neutral | |
| 02/06/2020 | — | Benchmark | Initiates Coverage On | → Buy | |
| 09/19/2019 | 95.21% | Barclays | $110 → $132 | Upgrades | Equal-Weight → Overweight |
| 08/05/2019 | 62.67% | Barclays | $131 → $110 | Maintains | Equal-Weight |
| 06/11/2019 | 93.73% | Barclays | → $131 | Initiates Coverage On | → Equal-Weight |
| 09/19/2018 | 299.29% | HC Wainwright & Co. | $257 → $270 | Maintains | Buy |
| 日期 | 上行/下行 | 分析公司 | 目标价格变化 | 评级变化 | 上一次/当前评级 |
|---|---|---|---|---|---|
| 2023/08/23 | 40.49% | 基准 | →$95 | 重申 | 购买→购买 |
| 08/09/2023 | 112.95% | HC Wainwright公司 | →$144 | 重申 | 购买→购买 |
| 07/25/2023 | 62.67% | 巴克莱 | $120→$110 | 维护 | 超重 |
| 06/02/2023 | 112.95% | HC Wainwright公司 | $135→$144 | 重申 | 购买→购买 |
| 02/21/2023 | 40.49% | 基准 | →$95 | 重申 | →购买 |
| 2022年12月23日 | 33.1% | 罗斯资本 | $85→$90 | 维护 | 买 |
| 2022年11月21日 | 77.46% | 巴克莱 | $150→$120 | 维护 | 超重 |
| 2022年10月25日 | 121.83% | 巴克莱 | $157→$150 | 维护 | 超重 |
| 09/02/2022 | 158.8% | 罗斯资本 | $185→$175 | 维护 | 买 |
| 07/05/2022 | 132.18% | 巴克莱 | $165→$157 | 维护 | 超重 |
| 05/16/2022 | 92.25% | 斯蒂芬斯公司 | $153→$130 | 维护 | 超重 |
| 02/22/2022 | 92.25% | 基准 | $180→$130 | 维护 | 买 |
| 02/18/2022 | 144.01% | 巴克莱 | $185→$165 | 维护 | 超重 |
| 09/22/2021 | 166.19% | 巴克莱 | $174→$180 | 维护 | 超重 |
| 07/30/2021 | 180.98% | 罗斯资本 | $200→$190 | 维护 | 买 |
| 05/04/2021 | 180.98% | 巴克莱 | $198→$190 | 维护 | 超重 |
| 02/04/2021 | 192.81% | 巴克莱 | $145→$198 | 维护 | 超重 |
| 02/04/2021 | 195.77% | 罗斯资本 | $195→$200 | 维护 | 买 |
| 02/04/2021 | 358.44% | HC Wainwright公司 | $229→$310 | 维护 | 买 |
| 10/21/2020 | 188.38% | 克雷格-哈勒姆 | $215→$195 | 维护 | 买 |
| 09/29/2020 | 188.38% | 罗斯资本 | $190→$195 | 重申 | →购买 |
| 08/04/2020 | 114.43% | 巴克莱 | $134→$145 | 维护 | 超重 |
| 04/08/2020 | 238.66% | HC Wainwright公司 | $237→$229 | 维护 | 买 |
| 03/24/2020 | - | Argus研究 | 评级下调 | 购买→Hold | |
| 03/10/2020 | - | 古根海姆 | 开始承保 | →中性 | |
| 02/06/2020 | - | 基准 | 开始承保 | →购买 | |
| 2019年09月19日 | 95.21% | 巴克莱 | $110→$132 | 升级 | 等重→超重 |
| 2019年08月05日 | 62.67% | 巴克莱 | $131→$110 | 维护 | 等重 |
| 2019年6月11日 | 93.73% | 巴克莱 | →$131 | 开始承保 | →等重 |
| 2018年09月19日 | 299.29% | HC Wainwright公司 | $257→$270 | 维护 | 买 |
What is the target price for Ligand Pharmaceuticals (LGND)?
Ligand PharmPharmticals(LGND)的目标价格是多少？
The latest price target for Ligand Pharmaceuticals (NASDAQ: LGND) was reported by Benchmark on August 23, 2023. The analyst firm set a price target for $95.00 expecting LGND to rise to within 12 months (a possible 40.49% upside). 9 analyst firms have reported ratings in the last year.
基准于2023年8月23日报道了Ligand制药(纳斯达克：LGND)的最新目标价。这家分析公司将目标价定为95.00美元，预计LGND将在12个月内升至(可能上涨40.49%)。去年有9家分析公司公布了评级。
What is the most recent analyst rating for Ligand Pharmaceuticals (LGND)?
Ligand PharmPharmticals(LGND)的最新分析师评级是多少？
The latest analyst rating for Ligand Pharmaceuticals (NASDAQ: LGND) was provided by Benchmark, and Ligand Pharmaceuticals reiterated their buy rating.
纳斯达克(GIC：LGND)的最新分析师评级由Benchmark提供，Ligand PharmPharmticals重申其买入评级。
When is the next analyst rating going to be posted or updated for Ligand Pharmaceuticals (LGND)?
Ligand PharmPharmticals(LGND)的下一次分析师评级将于何时发布或更新？
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Ligand Pharmaceuticals, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Ligand Pharmaceuticals was filed on August 23, 2023 so you should expect the next rating to be made available sometime around August 23, 2024.
分析师在进行了广泛的研究后得出股票评级，其中包括查阅公共财务报表，与Ligand PharmPharmticals的高管和客户交谈，以及听取收益电话会议。大多数分析师每三个月就会这样做一次，所以你每年应该会得到每家公司每家公司的4个评级。Ligand制药的上一次评级是在2023年8月23日提交的，所以你应该预计下一次评级将在2024年8月23日左右的某个时候提供。
Is the Analyst Rating Ligand Pharmaceuticals (LGND) correct?
分析师对Ligand制药(LGND)的评级正确吗？
While ratings are subjective and will change, the latest Ligand Pharmaceuticals (LGND) rating was a reiterated with a price target of $0.00 to $95.00. The current price Ligand Pharmaceuticals (LGND) is trading at is $67.62, which is within the analyst's predicted range.
虽然评级是主观的，并将发生变化，但最新的Ligand制药(LGND)评级被重申，目标价在0.00美元至95.00美元之间。Ligand PharmPharmticals(LGND)目前的交易价格为67.62美元，在分析师的预测范围内。